Immunosuppressed prostate cancer patients treated by brachytherapy seem to enjoy similar cancer control rates as the similarly treated nonimmunosuppressed population. It is recognized, however, that a much larger cohort of immunosuppressed patients would need to be studied to demonstrate statistical equivalence.